Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    59
    ...
ATC Name B/G Ingredients Dosage Form Price
N07CA01 BETAHISTINE ARROW GENERIQUES G Betahistine dihydrochloride - 24mg 24mg Tablet 749,864 L.L
N05AX12 ATYPRAL G Aripiprazole - 15mg 15mg Tablet 712,237 L.L
N07CA01 VASOSERC BID G Betahistine dihydrochloride - 24mg 24mg Tablet 840,861 L.L
A07BA51 EUCARBON B Rhubarbe - 25mg, Sulfur - 50mg, Senna - 105mg, Vegetal charcoal - 180mg Tablet 795,555 L.L
C09CA01 COZAAR B Losartan potassium - 50mg 50mg Tablet 1,420,634 L.L
N05AX12 JOSWE ARIPAL 15 G Aripiprazole - 15mg 15mg Tablet 2,413,541 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 20mg 20mg Tablet 1,091,712 L.L
L01EA02 SPRYCEL B Dasatinib - 70mg 70mg Tablet 212,274,841 L.L
N05AX12 PIRIFY G Aripiprazole - 15mg 15mg Tablet 795,555 L.L
C03CA01 LASIX B Furosemide - 40mg 40mg Tablet 120,946 L.L
C09CA01 LOSANET G Losartan potassium - 50mg 50mg Tablet 395,474 L.L
L01EA02 APO-DASATINIB G Dasatinib - 70mg 70mg Tablet 71,323,688 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
N03AA02 GARDENAL B Phenobarbital - 100mg 100mg Tablet 120,946 L.L
N07CA03 ZINASEN G Flunarizine (HCl) - 10mg 10mg Tablet 599,354 L.L
C03CA01 BIOLASOMIDE G Furosemide - 40mg 40mg Tablet 181,419 L.L
G04BE03 TOURNES G Sildenafil - 50mg 50mg Tablet 994,259 L.L
M01AB05 REMETHAN G Diclofenac sodium - 50mg 50mg Tablet 196,201 L.L
N05AX12 JOSWE ARIPAL 5 G Aripiprazole - 5mg 5mg Tablet 1,389,533 L.L
C09CA01 COZAAR B Losartan potassium - 100mg 100mg Tablet 1,740,596 L.L
N05AX12 PIRIFY G Aripiprazole - 5mg 5mg Tablet 614,328 L.L
C03CA01 FURESIX 40 G Furosemide - 40mg 40mg Tablet 166,381 L.L
C09CA01 LOSANET G Losartan potassium - 100mg 100mg Tablet 395,474 L.L
G04BE03 VIGORAM G Sildenafil citrate - 50mg 50mg Tablet 330,585 L.L
L01EA02 SPRYCEL B Dasatinib - 50mg 50mg Tablet 212,274,841 L.L
M05BB03 FOSAVANCE B Alendronic acid (sodium alendronate) - 70mg, Colecalciferol - 5600IU Tablet 1,988,887 L.L
N05AX12 XALIPRO G Aripiprazole - 5mg 5mg Tablet 1,746,995 L.L
L01EA02 APO-DASATINIB G Dasatinib - 50mg 50mg Tablet 71,323,688 L.L
L02BA01 TAMOXIFENE BIOGARAN G Tamoxifen (citrate) - 10mg 10mg Tablet 415,247 L.L
M05BB03 ACIDE ALENDRONIQUE/ VITAMINE D3 BGR G Alendronic acid - 70mg, Colecalciferol - 5600UI Tablet 815,712 L.L
    ...
    59
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026